Lovelace Biomedical Research Institute

Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization headquartered in Albuquerque, New Mexico, delivers Good Laboratory Practice (GLP) toxicology studies, animal model development, bioanalytical services, and preclinical research across infectious disease, drug development, radiation countermeasures, and tobacco-related outcomes to federal agencies as a prime contractor on 128 awards (84% of recent activity) and as a subcontractor on 24 awards (16%).

Lovelace operates across 27 distinct federal customer agencies with no set-aside designation, competing on full-and-open basis. The organization holds two named subsidiaries: Lovelace Biomedical and Environmental Research Institute, Inc., and Mind Research Network, a neuroimaging research entity that expands the parent organization's neuroscience research capabilities. Corporate identity as a tax-exempt not-for-profit positions the vendor outside traditional for-profit contracting dynamics; the organization's research footprint centers on NAICS 541711 (Research and Development in Biotechnology) and 541714 (Research and Development in the Physical, Engineering, and Life Sciences).

Customer concentration is extreme and highly favorable to Lovelace. The Defense Health Agency dominates by potential value: 10 awards carrying $10 billion in combined ceiling—anchored by a single $10 billion Defense Health Agency military medical research and development IDIQ (Omnibus IV) awarded June 20, 2022, with a June 19, 2032 completion date. The National Institute of Allergy and Infectious Diseases (NIAID) leads by award count (19 awards, $1.3 billion combined potential value) across vaccine evaluation and testing services. The Office of the Assistant Secretary for Preparedness and Response (ASPR) anchors biodefense and medical countermeasure work (11 awards, $398.1 million potential value), including $100 million in radiological/nuclear IDIQ capacity (RADNUC, awarded September 9, 2022) and $45 million in chemical threat animal model development (CHEM, awarded July 28, 2022). The National Center for Advancing Translational Sciences (NCATS) and Food and Drug Administration (FDA) round out the top five by dollars—$162 million and $119.5 million combined potential value, respectively. These five agencies account for 99% of combined potential value across the award portfolio.

Lovelace's IDIQ portfolio is substantial and deep. The organization holds nine named parent IDIQs with multi-year ordering periods and high ceilings: NIAID evaluation and testing services ($136.6 million, awarded September 30, 2025, through September 29, 2035), NIAID preclinical services for HIV therapeutics ($107.3 million, November 15, 2021–October 14, 2027), NIAID resources to advance pediatrics and HIV prevention science ($98.9 million, April 15, 2023–April 14, 2030), ASPR biological animal model and medical countermeasure development (BIO, $100 million, September 30, 2022–September 29, 2027), ASPR radiological/nuclear countermeasures (RADNUC, $100 million, September 9, 2022–September 8, 2027), ASPR chemical threat animal models (CHEM, $45 million, July 28, 2022–July 31, 2026), National Institute on Drug Abuse (NIDA) pharmacology studies and animal model development ($48.9 million, August 6, 2024–August 5, 2030), NCATS safety evaluation and toxicology studies ($48.6 million, June 20, 2024–June 19, 2030), FDA tobacco-related clinical outcomes ($25 million, September 26, 2023–September 29, 2028), and a legacy NIDA respiratory depression assessment IDIQ ($6.5 million, September 26, 2022–September 25, 2027). The top five parent vehicles by task-order count include legacy NIDA IDIQs (75N95019D00012 with 13 task orders worth $26.3 million, and 75N92019D00017 with 7 task orders worth $4.4 million).

Recent representative work exemplifies Lovelace's capability depth. A $136.6 million NIAID IDIQ for evaluation and testing services for vaccines, awarded September 30, 2025, consolidates the organization's position as a vaccine toxicology and immunogenicity partner; the first delivery order issued September 28, 2026, valued at $339,534, is for a GLP repeat dose toxicology study of a live-attenuated respiratory virus vaccine. An $8.8 million ASPR delivery order issued September 29, 2023, for acute radiation syndrome animal model performance verification (RADNUC 2201) includes rodent, rabbit, minipig, and non-human primate studies with completion targeted for April 17, 2027, conducted in Albuquerque, New Mexico, on a cost-plus-fixed-fee basis. FDA work includes a $7.1 million sole-source 24-month contract (awarded September 19, 2025) for electronic nicotine delivery system toxicological studies for the Center for Tobacco Products and a $3.0 million delivery order (awarded September 14, 2026) investigating abuse liability of electronic nicotine delivery system output power and heating design, conducted in Calverton, Maryland. NIDA work spans opioid-induced respiratory depression countermeasures—a $211,128 delivery order issued March 21, 2024, and terminated for convenience March 19, 2025 under Department of Government Efficiency cost efficiency initiatives—and gene therapy candidate efficacy evaluation in neuromuscular junction disease models ($4.0 million, awarded September 29, 2023, through June 30, 2028).

Activity trajectory shows year-over-year decline in new awards: 22 awards in FY2022, declining to 11 in FY2026 through the reporting date. The recompete cliff for the next twenty-four months is moderate: 23 awards with ultimate completion dates in the window carry combined potential value of $38.8 million. This reflects Lovelace's exposure to near-term renewals across FDA tobacco research, NIDA drug abuse treatment programs, and smaller NHLBI and NCATS toxicology task orders.

SCI-reportable invoicing of $28.1 million across FY2022–FY2024 (FY2025 data sparse at October 2026) tracks to a federal services workforce averaging 20–30 FTEs on prime service contracts annually. FY2023 peak invoicing of $14.8 million across 30.5 FTEs suggests government-paid rate scale of a median $224.76 per hour across the portfolio, with specialist labor reaching $667.74 per hour at the 90th percentile and non-labor or timing-misaligned reimbursables driving $0.00 per hour entries at the 10th percentile. Lovelace self-performs all reported SCI labor on prime contracts (0% sub-hours share); the organization does not route significant service-contract delivery through subcontractors.

Lovelace operates as a subcontractor to other primes on grant-funded research where the prime grantees are university consortia and research institutes. Named prime grantees include the University of New Mexico, University of Pennsylvania, Columbia University, Emory University, and Father Flanagan's Boys' Home across NIH grants for trauma-related neurocognitive outcomes, prenatal alcohol exposure research, infectious disease countermeasures, and behavioral health in forensic populations. The Mind Research Network subsidiary serves as a data-collection and neuroimaging-analysis entity partnered with these prime recipients for multimodal brain imaging (fMRI, MEG, MRI) across NIH-funded longitudinal studies. Sub-award relationships include Astrix Technology LLC, Envision Now LLC, Medical Science & Computing LLC, Westwind Computer Products Inc., and Axle Informatics LLC on NHLBI Catalyze Program preclinical services, partial-body irradiation studies in nonhuman primates, and infectious disease drug concentration bioanalysis.

Federal grant footprint is substantial and growing. Lovelace is a grant recipient (not subrecipient) under NIAA (National Institute on Alcohol Abuse and Alcoholism), NIDA, National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Institute of Mental Health, Defense Health Agency, National Heart Lung and Blood Institute, and NSF Office of Integrative Activities. Representative recent grants include a $2.69 million NIDA cooperative agreement (CFDA 93.279, Drug Use and Addiction Research Programs, awarded September 30, 2025) for transcranial alternating current stimulation to enhance motivational interviewing for substance use disorder treatment, a $1.71 million NIAA project grant (CFDA 93.273, Alcohol Research Programs, awarded September 25, 2025) for music training intervention in children with Fetal Alcohol Spectrum Disorder, and a $2.6 million NSF Integrative Activities equipment grant (CFDA 47.083, awarded September 1, 2025) for acquisition of a MEGIN TRIUS NEO magnetoencephalography system with integrated helium recovery equipment at the Albuquerque facility. Defense Health Agency grants span traumatic brain injury biomarker validation (cooperative agreement, awarded June 1, 2024) and altitude effects in polytrauma transport modeling (cooperative agreement, awarded August 15, 2022). Lovelace also holds NIH grant awards spanning neurocognitive deficits in incarcerated women, Lewy body disease microbiome-gut-brain dysfunction, post-acute COVID-19 cognitive sequelae, and fentanyl-induced respiratory depression mechanisms—representing a diversified grant portfolio spanning behavioral health, neuroscience, and emergency medicine.

The organization competes predominantly on full-and-open basis across HHS and DoD customers; no 8(a), HUBZone, SDVOSB, WOSB, or other set-aside categories characterize the prime footprint. As a not-for-profit research entity, Lovelace operates under cost-plus-fixed-fee and firm-fixed-price pricing structures typical of federal research contracting. The award portfolio shows no significant teaming relationships with for-profit contractors; subcontracting is routed to IT infrastructure, data management, and specialized testing vendors under prime grants rather than used as a delivery model on contracts.